Company
FSD Pharma Inc.
Headquarters: Toronto, ON, Canada
Employees: 9
CEO: Mr. Anthony John Durkacz
Market Cap
$36.0 Million
USD as of Jan. 1, 2024
FSD Pharma Inc. Categories
Canada Healthcare Drug Manufacturers—Specialty & GenericCanada Healthcare Canada Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.
Top 1-year algo backtest: +191.38%
$10,000 in June 2023 would now be $29,138 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
FSD Pharma Inc. has the following listings and related stock indices.
Stock: NASDAQ: HUGE wb_incandescent
Stock: CSE: HUGE wb_incandescent